Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk

Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focusing on defeating serious chronic diseases, particularly diabetes [2] - The company employs approximately 69,000 people across 80 countries and markets its products in around 170 countries [2] Market Opportunity - The weight loss market is expanding, with Novo Nordisk being a key provider through products like Ozempic and Wegovy, representing a multi-trillion-dollar opportunity [3] - The launch of NVOX, the world's first single-stock leveraged ETF for Novo Nordisk, aims to provide retail investors with 2X daily long leveraged exposure to the stock's price movements [1][3] Product Launch - Defiance ETFs launched NVOX to offer a unique trading tool for tactical investors, allowing them to gain enhanced exposure to Novo Nordisk's share price without needing a margin account [1][3] - NVOX does not invest directly in Novo Nordisk, which introduces a higher degree of risk due to its focus on a single stock [1]